Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Natural killer cell: major player of innate immunity
- Innate Lymphoid Cells (ILC)
- NK cell functions
- The missing–self hypothesis
- HLA class I specific inhibitory receptors
- The NK receptor repertoire (autologous setting)
- The receptors for HLA-C
- Triggering NK receptors & their cellular ligands
- Known ligands for activating NK receptors
- NK cells and potential target cells
- CD56dim & 56bright NK cell subsets function
- NK cell differentiation model
- The NK cell microenvironment
- NK-DC interactions in inflamed tissues
- DC-editing
- NK-DC crosstalk
- IL 12 exposed NK cells can kill iDCs
- Cytokine exposure affects NK cell functions
- Different cells modulate different NK-cell responses
- NK cells contribute to innate & adaptive immunity
- Tumor microenvironment effect on NK cell function
- NSCLC-NK cells localize to reactive tumor stroma
- NK cells and the tumor microenvironment
- Tumor-derived immunosuppressive factors
- NK cells in high risk leukemias therapy
- Human NK cells (autologous setting)
- Human NK cells (allogeneic setting)
- NK cell differentiation: alloreactive cells
- T-depleted haploidentical HSC transplantation
- Alloreactive NK cells in haploidentical HSCT
- Haploidentical BM transplantation: AML
- Alloreactive NK cells: generation & therapeutic role
- Pediatric patient high risk leukemia treatment
- Alloreactive NK cell identification & donor selection
- Alloreactive NK cell subset definition
- Alloreactive NK cells and their cytolytic effect
- Functional alloreactive NK cells persist in patients
- Haplo-mismatch alloreactive NK cytolytic activity
- Alloreactive NK cell subset size & clinical outcome
- HSCT results depend on alloreactive NK cells
- Haploidentical HSCT in pediatric patients: results
- NK alloreactivity & leukemia-free survival
- Conclusions (Haplo-HSCT)
- Current protocols: donor selection
- Current protocols: leukemia relapses and GvHD
- Time to alloreactive NK cell appearance
- Haploidentical transplantation: current protocols
- Novel strategy from haploidentical donors
Topics Covered
- NK cells and their contribution to innate & adaptive immunity
- Triggering NK receptors and their cellular ligands
- Effect of the tumor microenvironment on NK cell function
- NK cells and haploidentical hematopeoitic stem cell therapy (HSCT) in high risk leukemias
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Moretta, L. (2015, July 30). Human NK cells [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/JSLY8773.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Lorenzo Moretta has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: The Immune System - Key Concepts and Questions
Other Talks in the Series: Immunotherapy of Cancer
Transcript
Please wait while the transcript is being prepared...
0:04
This is the cells we will talk about,
the NK cells seen in blood smear.
As you can see, they are large
granular lymphocytes with granules
that are responsible for killing
of tumor cells or virus infected cells.
0:24
NK cells originate from
hematopoietic stem cells
and belong to a
growing family that
we call Innate Lymphoid Cells,
ILC, which all derive
from an Id2 positive resource.
And depending on the cytokine
milieu and on the transcription
factors that are being activated,
these resource can give
rise to different group of ILC.
NK cells, as you can see in these
figures, belong to group one.
ILC is those cells which release
interferon gamma and have also,
at least in the case of
NK cells, the ability
to kill viral infected cells.
1:08
NK cells serve a number
of functional capability,
and we can group these
functional abilities
in cytotoxicity, which
means their ability
to kill tumor or leukemia cells.
They were discovered really for
their ability to kill tumors,
but they also kill virus
infected cells, which
is a very important
function, and they perform
also DC editing, as we'll discuss.
We should not forget, NK cells
are important cytokine producers.
So they can induce
inflammatory response,
regulate adaptive immune response,
regulate hematopoiesis, induce
DC maturity, and also to
play some important role
at the decidual level.
They are able to proliferate in
response to cytokines activate.